



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: in.pg.com

January 31, 2024

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

**Sub: Unaudited Financial Results for the quarter ended December 31, 2023 and Interim Dividend for Financial Year 2023-24**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 12.21 p.m. and ended at 12:48 p.m.), the Unaudited Financial Results for the quarter ended December 31, 2023 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended December 31, 2023;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2023 furnished by Statutory Auditors of the Company.

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2023-24 of ₹ 160 per Equity Share (Face Value of Rs. 10/- each). This interim dividend includes a one-time special dividend of ₹ 60 per equity share to commemorate 60 years of serving consumers, customers, shareholders, employees, and society. The dividend shall be paid on or before February 29, 2024.

As informed earlier in our letter dated January 19, 2024, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 9, 2024.

Kindly take the same on record and oblige.

Thanking you,  
Yours faithfully,

For Procter & Gamble Hygiene and Health Care Limited

**Flavia Machado**  
**Senior Legal Manager- Legal and Secretarial**



Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office: P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
(91 – 22) 2826 6000 phone  
(91 – 22) 2826 7337 fax  
Website: in.pg.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 31st DECEMBER 2023

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st Dec 2023	Preceding Three Months Ended 30th Sept 2023	Corresponding Three Months Ended 31st Dec 2022	Six Months Ended 31st Dec 2023	Corresponding Six Months Ended 31st Dec 2022	Year Ended 30th June 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1 Income</b>						
Sale of products	1 13 093	1 13 506	1 13 424	2 26 599	2 17 516	3 90 521
Other operating revenues	250	329	315	579	712	1 269
<b>2 Revenue from operations</b>	<b>1 13 343</b>	<b>1 13 835</b>	<b>1 13 739</b>	<b>2 27 178</b>	<b>2 18 228</b>	<b>3 91 790</b>
3 Other income	1 558	1 577	931	3 135	1 604	4 058
<b>Total income (2+3)</b>	<b>1 14 901</b>	<b>1 15 412</b>	<b>1 14 670</b>	<b>2 30 313</b>	<b>2 19 832</b>	<b>3 95 848</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	21 457	21 652	22 510	43 109	49 140	84 755
b) Purchases of stock-in-trade (Traded goods)	21 887	22 285	20 581	44 172	41 723	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1 753	574	5 514	2 327	1 073	( 853)
d) Employee benefits expense	5 470	6 372	5 693	11 842	10 819	20 579
e) Finance costs	255	189	386	444	481	1 138
f) Depreciation and amortization expense	1 426	1 430	1 441	2 856	2 837	5 836
g) Advertising & sales promotion expenses	12 670	15 347	11 076	28 017	26 645	42 652
h) Other expenses	19 132	19 116	19 316	38 248	38 381	75 393
<b>Total expenses</b>	<b>84 050</b>	<b>86 965</b>	<b>86 517</b>	<b>1 71 015</b>	<b>1 71 099</b>	<b>3 11 901</b>
<b>5 Profit before tax (2+3-4)</b>	<b>30 851</b>	<b>28 447</b>	<b>28 153</b>	<b>59 298</b>	<b>48 733</b>	<b>83 947</b>
<b>6 Tax expense</b>						
a) Current tax	8 163	7 533	8 104	15 696	13 519	23 052
b) Deferred tax	( 444)	( 155)	( 737)	( 599)	( 1 013)	( 1 208)
c) Prior year tax adjustments (Refer note 5)	242	---	39	242	39	( 5 711)
	<b>7 961</b>	<b>7 378</b>	<b>7 406</b>	<b>15 339</b>	<b>12 545</b>	<b>16 133</b>
<b>7 Profit for the period (5-6)</b>	<b>22 890</b>	<b>21 069</b>	<b>20 747</b>	<b>43 959</b>	<b>36 188</b>	<b>67 814</b>
<b>8 Other comprehensive income</b>						
Items that will not be reclassified to profit or loss:						
Remeasurement of the defined benefit plans	745	( 250)	( 695)	495	( 513)	( 999)
Income tax effect on above	( 188)	63	175	( 125)	129	251
<b>Total other comprehensive income for the period</b>	<b>557</b>	<b>( 187)</b>	<b>( 520)</b>	<b>370</b>	<b>( 384)</b>	<b>( 748)</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>23 447</b>	<b>20 882</b>	<b>20 227</b>	<b>44 329</b>	<b>35 804</b>	<b>67 066</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>						<b>91 357</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>						
a) Basic	70.51	64.91	63.91	135.42	111.48	208.91
b) Diluted	70.51	64.91	63.91	135.42	111.48	208.91

See accompanying notes to the financial results

Notes:

## 1 Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at	As at
	31 <sup>st</sup> Dec 2023 (Unaudited)	30 <sup>th</sup> June 2023 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	16 002	17 004
Capital work-in-progress	1 976	2 276
Financial assets		
(i) Loans	2 834	2 737
(ii) Other financial assets	944	909
Deferred tax assets (Net)	6 561	6 554
Non-current tax assets (Net)	24 847	24 622
Other non-current assets	8 463	10 060
<b>Total non-current assets</b>	<b>61 627</b>	<b>64 162</b>
<b>Current assets</b>		
Inventories	18 545	21 980
Financial assets		
(i) Trade receivables	29 710	21 628
(ii) Cash and cash equivalents	68 843	96 383
(iii) Bank balances other than (ii) above	1 399	1 416
(iv) Loans	35 386	369
(v) Other financial assets	2 979	3 277
Other current assets	4 163	4 517
	<b>1 61 025</b>	<b>1 49 570</b>
Non current assets held for sale	----	----
<b>Total current assets</b>	<b>1 61 025</b>	<b>1 49 570</b>
<b>Total Assets</b>	<b>2 22 652</b>	<b>2 13 732</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	3 246	3 246
Other equity	1 02 004	91 357
<b>Total Equity</b>	<b>1 05 250</b>	<b>94 603</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	26	84
Provisions	10 840	10 542
<b>Total non-current liabilities</b>	<b>10 866</b>	<b>10 626</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	332	319
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	965	1 946
Total outstanding dues of creditors other than micro enterprises and small enterprises	92 629	95 161
(iii) Other financial liabilities	2 000	2 538
Other current liabilities	5 891	4 934
Provisions	513	1 035
Current tax liabilities (net)	4 206	2 570
<b>Total current liabilities</b>	<b>1 06 536</b>	<b>1 08 503</b>
<b>Total Liabilities</b>	<b>1 17 402</b>	<b>1 19 129</b>
<b>Total Equity and Liabilities</b>	<b>2 22 652</b>	<b>2 13 732</b>

## 2 Statement of Cash Flows

(₹ in Lakhs)

Particulars	Half Year Ended 31 <sup>st</sup> Dec 2023 (Unaudited)	Year Ended 30 <sup>th</sup> June 2023 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
<b>Profit before tax</b>	<b>59 298</b>	<b>83 947</b>
<b>Adjustments for:</b>		
Depreciation and amortization expense	2 856	5 836
Loss on disposal of property, plant and equipment	1	83
Finance costs	444	1 138
Allowance for doubtful receivables (Net of recovery)	332	109
Interest income	( 2 779)	( 3 508)
Net foreign exchange (gain) / loss	( 212)	38
Inventory written off (net of Insurance claims recovered)	496	896
Provisions no longer required written back	( 279)	( 408)
Expense recognised in respect of equity settled share based payments	402	848
<b>Operating profit before working capital changes</b>	<b>60 559</b>	<b>88 979</b>
<b>Working capital adjustments</b>		
(Increase) in trade and other receivables	( 8 407)	( 2 511)
Decrease / (Increase) in financial assets	245	( 866)
Decrease in inventories	2 939	526
Decrease / (Increase) in other assets	1 951	( 2 029)
(Decrease) / Increase in trade and other payables	( 2 072)	20 695
(Decrease) / Increase in provisions	( 86)	737
<b>Cash generated from operations</b>	<b>55 129</b>	<b>1 05 531</b>
Income taxes paid	( 14 061)	( 22 954)
<b>Net cash generated from operating activities</b>	<b>41 068</b>	<b>82 577</b>
<b>B. Cash Flows from Investing Activities</b>		
Loan given to affiliates	( 70 000)	----
Loan repaid by affiliates	35 000	----
Interest received	2 683	3 451
Payment to acquire property, plant and equipment	( 2 087)	( 4 444)
Proceeds from sale of property, plant and equipment	12	2
<b>Net cash (used in) investing activities</b>	<b>( 34 392)</b>	<b>( 991)</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend paid	( 34 084)	( 47 068)
Principal payment of lease liabilities	( 45)	( 107)
Interest paid on lease liabilities	( 5)	( 12)
Interest paid other than on lease liabilities	( 82)	( 514)
<b>Net cash (used in) financing activities</b>	<b>( 34 216)</b>	<b>( 47 701)</b>
<b>Net (decrease) / increase in cash and cash equivalents</b>	<b>( 27 540)</b>	<b>33 885</b>
Cash and cash equivalents at the beginning of the year	<b>96 383</b>	<b>62 498</b>
<b>Cash and cash equivalents at the end of the period/year</b>	<b>68 843</b>	<b>96 383</b>

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 31, 2024 and have been subjected to a limited review by the Statutory Auditors of the Company.
- The Board of Directors at its meeting held on January 31, 2024 have declared for the current year an interim dividend of ₹ 160 per equity share of face value ₹ 10 each (including a one-time special dividend of ₹ 60 per equity share) aggregating to ₹ 51,937 lakhs.
- During the previous year ended June 2023, the Company reversed tax provisions amounting to ₹ 5,844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

Vaidyanathan  
Digitally signed by  
Vaidyanathan  
Viswanathan  
Lalgudi  
Date: 2024.01.31  
12:37:34 +05'30'

LV Vaidyanathan  
Managing Director

Place: Mumbai  
Date: January 31, 2024

**REVIEW REPORT  
TO THE BOARD OF DIRECTORS  
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** (“the Company”) for the quarter and half year ended December 31, 2023, together with the Statement of Unaudited Assets and Liabilities, Unaudited Cash Flows Statement and the notes thereon, (“the Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement, which is the responsibility of the Company’s Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 31, 2024, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (“the Act”) read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS**

Firm Regn. No.: 104607W / W100166

ROSHNI RAYOMAND  
MARFATIA

*Roshni R Marfatia*

**PARTNER**

M. No.: 106548

UDIN: 24106548BKCSSM2824

Mumbai: January 31, 2024.



Procter & Gamble Hygiene  
and Health Care Limited  
CIN : L24239MH1964PLC012971  
Registered Office: P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
(91 – 22) 2826 6000 phone  
(91 – 22) 2826 7337 fax  
Website: in.pg.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 31st DECEMBER 2023

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st Dec 2023	Preceding Three Months Ended 30th Sept 2023	Corresponding Three Months Ended 31st Dec 2022	Six Months Ended 31st Dec 2023	Corresponding Six Months Ended 31st Dec 2022	Year Ended 30th June 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1 Income</b>						
Sale of products	1 13 093	1 13 506	1 13 424	2 26 599	2 17 516	3 90 521
Other operating revenues	250	329	315	579	712	1 269
<b>2 Revenue from operations</b>	<b>1 13 343</b>	<b>1 13 835</b>	<b>1 13 739</b>	<b>2 27 178</b>	<b>2 18 228</b>	<b>3 91 790</b>
3 Other income	1 558	1 577	931	3 135	1 604	4 058
<b>Total income (2+3)</b>	<b>1 14 901</b>	<b>1 15 412</b>	<b>1 14 670</b>	<b>2 30 313</b>	<b>2 19 832</b>	<b>3 95 848</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	21 457	21 652	22 510	43 109	49 140	84 755
b) Purchases of stock-in-trade (Traded goods)	21 887	22 285	20 581	44 172	41 723	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1 753	574	5 514	2 327	1 073	( 853)
d) Employee benefits expense	5 470	6 372	5 693	11 842	10 819	20 579
e) Finance costs	255	189	386	444	481	1 138
f) Depreciation and amortization expense	1 426	1 430	1 441	2 856	2 837	5 836
g) Advertising & sales promotion expenses	12 670	15 347	11 076	28 017	26 645	42 652
h) Other expenses	19 132	19 116	19 316	38 248	38 381	75 393
<b>Total expenses</b>	<b>84 050</b>	<b>86 965</b>	<b>86 517</b>	<b>1 71 015</b>	<b>1 71 099</b>	<b>3 11 901</b>
<b>5 Profit before tax (2+3-4)</b>	<b>30 851</b>	<b>28 447</b>	<b>28 153</b>	<b>59 298</b>	<b>48 733</b>	<b>83 947</b>
<b>6 Tax expense</b>						
a) Current tax	8 163	7 533	8 104	15 696	13 519	23 052
b) Deferred tax	( 444)	( 155)	( 737)	( 599)	( 1 013)	( 1 208)
c) Prior year tax adjustments (Refer note 5)	242	---	39	242	39	( 5 711)
	7 961	7 378	7 406	15 339	12 545	16 133
<b>7 Profit for the period (5-6)</b>	<b>22 890</b>	<b>21 069</b>	<b>20 747</b>	<b>43 959</b>	<b>36 188</b>	<b>67 814</b>
<b>8 Other comprehensive income</b>						
Items that will not be reclassified to profit or loss:						
Remeasurement of the defined benefit plans	745	( 250)	( 695)	495	( 513)	( 999)
Income tax effect on above	( 188)	63	175	( 125)	129	251
<b>Total other comprehensive income for the period</b>	<b>557</b>	<b>( 187)</b>	<b>( 520)</b>	<b>370</b>	<b>( 384)</b>	<b>( 748)</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>23 447</b>	<b>20 882</b>	<b>20 227</b>	<b>44 329</b>	<b>35 804</b>	<b>67 066</b>
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246	3 246	3 246
11 Other Equity						91 357
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>						
a) Basic	70.51	64.91	63.91	135.42	111.48	208.91
b) Diluted	70.51	64.91	63.91	135.42	111.48	208.91

See accompanying notes to the financial results

Notes:

## 1 Statement of Assets and Liabilities

(₹ in Lakhs)

Particulars	As at	As at
	31 <sup>st</sup> Dec 2023 (Unaudited)	30 <sup>th</sup> June 2023 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	16 002	17 004
Capital work-in-progress	1 976	2 276
Financial assets		
(i) Loans	2 834	2 737
(ii) Other financial assets	944	909
Deferred tax assets (Net)	6 561	6 554
Non-current tax assets (Net)	24 847	24 622
Other non-current assets	8 463	10 060
<b>Total non-current assets</b>	<b>61 627</b>	<b>64 162</b>
<b>Current assets</b>		
Inventories	18 545	21 980
Financial assets		
(i) Trade receivables	29 710	21 628
(ii) Cash and cash equivalents	68 843	96 383
(iii) Bank balances other than (ii) above	1 399	1 416
(iv) Loans	35 386	369
(v) Other financial assets	2 979	3 277
Other current assets	4 163	4 517
	<b>1 61 025</b>	<b>1 49 570</b>
Non current assets held for sale	----	----
<b>Total current assets</b>	<b>1 61 025</b>	<b>1 49 570</b>
<b>Total Assets</b>	<b>2 22 652</b>	<b>2 13 732</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share capital	3 246	3 246
Other equity	1 02 004	91 357
<b>Total Equity</b>	<b>1 05 250</b>	<b>94 603</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	26	84
Provisions	10 840	10 542
<b>Total non-current liabilities</b>	<b>10 866</b>	<b>10 626</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	332	319
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	965	1 946
Total outstanding dues of creditors other than micro enterprises and small enterprises	92 629	95 161
(iii) Other financial liabilities	2 000	2 538
Other current liabilities	5 891	4 934
Provisions	513	1 035
Current tax liabilities (net)	4 206	2 570
<b>Total current liabilities</b>	<b>1 06 536</b>	<b>1 08 503</b>
<b>Total Liabilities</b>	<b>1 17 402</b>	<b>1 19 129</b>
<b>Total Equity and Liabilities</b>	<b>2 22 652</b>	<b>2 13 732</b>

